Intrexon, which is developing synthetic biology technologies to improve drugs and food, raised $160 million in an upsized IPO by offering 10.0 million shares at $16, the high end of the range of $14 to $16. The company had originally planned to offer 8.3 million shares. Intrexon plans to list on the NYSE under the symbol XON. Intrexon initially filed confidentially on 5/10/2013. J.P. Morgan and Barclays acted as lead managers on the deal.
